Workflow
5月港股创新药ETF涨超9%，A500ETF基金(512050)涨近2%，本周继续“吸金”2.65亿元
Ge Long Hui·2025-05-30 08:12

Market Performance - In May, the A-share market experienced fluctuations, peaking at 3400 points before retreating, with the Wande Microplate Index leading the market with a cumulative increase of over 10% [1] - The CSI 2000 index followed with a 4.1% increase, while the ChiNext 50 and ChiNext Index rose by 3.12% and 3.04% respectively [1][2] - The overall performance of the STAR Market indices was poor, with the STAR 100 and STAR 50 declining by 2.84% and 3.5% respectively [1][2] ETF Performance - The "Global Vision, Betting on China" top ten core ETFs reported a 2% increase in May, with a cumulative rise of 4.59% for the year [4] - The Hong Kong Innovative Drug ETF led the monthly performance with a 9.32% increase, and a remarkable 40.69% rise year-to-date [4][9] - The A500 ETF Fund (512050) increased by 1.97% in May, continuing to attract capital with an inflow of 265 million yuan in the first four days of the week [4][5] Investment Outlook - CITIC Securities anticipates a potential bull market for both Hong Kong and A-share markets, with a key entry point expected between the third and fourth quarters [7] - The trend is shifting towards core assets, driven by a surge in A-share companies going public in Hong Kong, which is expected to activate trading in corresponding A-shares [7] - The CSI A500 index is characterized by high market capitalization, profitability, and growth, with an expected return of 22% over the next year, supported by strong earnings growth [8] Pharmaceutical Sector Insights - The recent surge in the Hong Kong innovative drug sector is attributed to multiple factors, including significant licensing agreements and collaborations with multinational pharmaceutical companies [11] - The first quarter of 2025 saw a 180% year-on-year increase in transaction volume for domestic innovative drugs going abroad, indicating a strong international competitive position [11] - The application of AI in drug discovery and clinical trial design is emerging as a new variable, with domestic companies actively developing AI-assisted research platforms [12]